654655-80-8

(Rac)-Bedaquiline is the racemic form of Bedaquiline. Bedaquiline (TMC207) acts as a diarylquinoline agent that targets the c- and ε-subunits to inhibit Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase. It possesses uncoupler activity and is employed in the treatment of multidrug-resistant tuberculosis.

(Rac)-Bedaquiline-D6 is a deuterium-labeled version of Bedaquiline. Bedaquiline (TMC207) is a diarylquinoline compound that targets the c and ε subunits to inhibit Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase. Levomefolic acid exhibits uncoupling activity and is used in the treatment of multidrug-resistant tuberculosis.

Bedaquiline (Standard) is a reference standard for research and analysis in studies involving Bedaquiline. Bedaquiline (R207910) is an anti-tuberculosis drug which selectively inhibit the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis.

Bedaquiline (R207910) is an anti-tuberculosis drug which selectively inhibit the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis.

(1S,2R)-Bedaquiline ((1S,2R)-TMC207) is a pharmaceutical intermediate utilized in the synthesis of various active compounds.

Bedaquiline fumarate (TMC207), a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections. It blocks the proton pump for ATP synthase of mycobacteria. It is the first member of a new class of drugs called diarylquinolines.